Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1957 | 2 |
1960 | 1 |
1967 | 1 |
1975 | 6 |
1976 | 8 |
1977 | 8 |
1978 | 11 |
1979 | 13 |
1980 | 11 |
1981 | 12 |
1982 | 16 |
1983 | 16 |
1984 | 21 |
1985 | 16 |
1986 | 13 |
1987 | 10 |
1988 | 17 |
1989 | 17 |
1990 | 13 |
1991 | 8 |
1992 | 13 |
1993 | 13 |
1994 | 12 |
1995 | 9 |
1996 | 13 |
1997 | 14 |
1998 | 13 |
1999 | 14 |
2000 | 16 |
2001 | 20 |
2002 | 23 |
2003 | 32 |
2004 | 26 |
2005 | 23 |
2006 | 22 |
2007 | 23 |
2008 | 24 |
2009 | 25 |
2010 | 41 |
2011 | 32 |
2012 | 41 |
2013 | 41 |
2014 | 46 |
2015 | 48 |
2016 | 59 |
2017 | 66 |
2018 | 50 |
2019 | 59 |
2020 | 61 |
2021 | 87 |
2022 | 64 |
2023 | 49 |
2024 | 29 |
Search Results
1,200 results
Results by year
In multivariate analysis, complex karyotype predicted lower response (p = 0.0001), while pretreatment with hypomethylating agents (p = 0.02) and adverse European LeukemiaNet 2017 genetic risk (p < 0.0001) were associated with lower OS. Allogeneic hematopoi
…When compared with placebo, 24-h glucose concentrations were significantly lower when cinnamon was administered [mixed-models; effect size (ES) = 0.96; 95 % confidence interval (CI): -2.9, -1.5; P < 0.001]. Similarly, the mean net-area-under-the-curve (netAUC) for gluco
…Hyperlipidemia was confirmed in ApoE(-/-) rats by elevated plasma cholesterol (p < 0.001) and triglyceride (p = 0.025) levels. Early atherosclerosis was supported by increased intima/media thickness ratio (p < 0.01) and ED1-positive macrophage influx in
…Hyperlipidemia was confirmed in ApoE(-/-) rats by elevated plasma cholesterol (p < 0.001) and triglyceride (p = 0.025) leve
…In phase III trials, margetuximab and neratinib combinations demonstrated significant 1.3-month (hazard ratio, HR = 0.71, p < 0.001) and 0.1-month (HR = 0.76, p = 0.006) net improvements in median progression-free survival (PFS), respectively, with no significant
…In phase III trials, margetuximab and neratinib combinations demonstrated significant 1.3-month (hazard ratio, HR = 0.71, p < 0.00
…